Recently, immune edition has been recognized as a new hallmark of cancer. In this respect, some clinical trials in breast cancer have reported imppressive outcomes related to laboratory immune findings, especially in the neoadjuvant and metastatic setting. Infiltration by tumor infiltrating lymphocytes (TIL) and their subtypes, tumor-associated macrophages (TAM) and myeloid-derived suppressive cells (MDSC) seem bona fide prognostic and even predictive biomarkers, that will eventually be incorporated into diagnostic and therapeutic algorithms of breast cancer. In addition, the complex interaction of costimulatory and coinhibitory molecules on the immune synapse and the different signals that they may exert represent another exciting field to explore. In this review we try to summarize and elucidate these new concepts and knowledge from a translational perspective focusing on breast cancer, paying special attention to those aspects that might have more significance in clinical practice and could be useful to design successful therapeutic strategies in the future. © 2013 Luis de la Cruz-Merino et al.
CITATION STYLE
De La Cruz-Merino, L., Barco-Sánchez, A., Henao Carrasco, F., Nogales Fernández, E., Vallejo Benítez, A., Brugal Molina, J., … Ibáñez Martínez, J. (2013). New insights into the role of the immune microenvironment in breast carcinoma. Clinical and Developmental Immunology, 2013. https://doi.org/10.1155/2013/785317
Mendeley helps you to discover research relevant for your work.